Objective assessment of hyperandrogenism and modern ideas on PCOS treatment

Archives of Perinatal Medicine

Volumn 17, Issue 4, 2011, Pages 210-216

  Katulski, Krzysztof ^a   Meczekalski, Błazj ^a  

^a POZNAN UNIVERSITY OF MEDICAL SCIENCES   (Poland)

Author keywords

Hyperandrogenism; Infertility; Ovary syndrome

Indexed keywords

EID: 84859114270     PISSN: 15050580     EISSN: 15084868     Source Type: Journal    
DOI: None     Document Type: Article

References (38)

1. Bre{ogonek}borowicz G.H. (2005) Obstetrics and gynecology. PZWL, 705-758.
2. Ledger W.L., Sheffield S.L. Atkin H. Li Wei Cho (2010) Long-Term Consequences of Polycystic Ovary Syndrome, Green-top guideline 24: 304-309.
3. Katulski K., Warenik-Szymankiewicz A., Trzeciak W.H. (1995) Molecular background of PCOS. Ginek. Pol. 66: 561-568.
4. Katulski K., Bornstein S., Figiel M. (1998) Typical hormonal profiles are accompanied by increased immunoreactivity of theca folliculi steroid 17 alpha-hydroxylase P450 in polycystic ovary syndrome. J. Endocrinol. Invest. 21: 304-309.
5. Consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome. The Rotterdam ESHRE/ASRM-Sponsored PCOS Consensus Workshop Group Revised 2003 Fertility and Sterility 2004: 81, 19-25.
6. Teede H., Deeks A., Moran L. (2010) Polycystic ovary syndrome: a complex condition with psychological, reproductive and metabolic manifestations that impacts on health. BMC Med. 30, 8: 41.
7. Azziz R., Carmina E., Dewailly D. et al. (2009) Task Force on the Phenotype of the Polycystic Ovary Syndrome of The Androgen Excess and PCOS Society. The Androgen Excess and PCOS Society criteria for the polycystic ovary syndrome: the complete task force report. Fertil. Steril. 91(2): 456-88.
8. Rosenfield R.L. (2005) Clinical practice. Hirsutism. N. Engl. J. Med. 353(24): 2578-88.
9. Yildiz B.O., Woods K.S., Stanczyk F. et al. (2004) Stability of adrenocortical steroidogenesis over time in healthy women and women with polycystic ovary syndrome. J. Clin. Endocrinol. Metab. 89(11): 5558-62.
10. Rosner W., Auchus R.J., Azziz R. et al (2007) Position statement: utility, limitations, and pitfalls in measuring testosterone: an Endocrine Society position statement. J. Clin. Endocrinol. Metab. 92 (2): 405-13.
11. Azziz R., Sanchez L.A., Knochenhauer E.S. et al. (2004) Androgen excess in women: experience with over 1000 consecutive patients. J. Clin. Endocrinol. Metab. 89: 453-462.
12. Guyatt G., Weaver B., Cronin L. et al. (2004) Health-related quality of life in women with polycystic ovary syndrome, a self-administered questionnaire, was validated. J. Clin. Epidemiol. 57: 1279-1287.
13. Espinós J.J., Calaf J., Estadella J. et al. (2010) Hirsutism scoring in polycystic ovary syndrome: concordance between clinicians' and patients' self-scoring. Fertil .Steril. 94(7): 2815-6.
14. Archer J.S., Chang R.J. (2004) Hirsutism and acne in polycystic ovary syndrome. Best Pract. Res. Clin. Obstet. Gynaecol. 18(5): 737-54.
15. Williamson K., Gunn A.J., Johnson N. et al. (2001) The impact of ethnicity on the presentation of polycystic ovarian syndrome. Aust. N. Z. J. Obstet. Gynaecol. 41(2): 202-6.
16. Ferriman D., Gallwey J.D. (1961) Clinical assessment of body hair growth in women. J. Clin. Endocrinol. Metab. 21: 1440-7.
17. Espinós J.J., Calaf J., Estadella J. et al. (2010) Hirsutism scoring in polycystic ovary syndrome: concordance between clinicians' and patients' self-scoring. Fertil. Steril. 94(7): 2815-6.
18. Burkhart C.N., Gottwald L. (2003) Assessment of etiologic agents in acne pathogenesis. Skinmed 2(4): 222-8.
19. Goulden V., Stables G.I., Cunliffe W.J. (1999) Prevalence of facial acne in adults. J. Am. Acad. Dermatol. 41(4): 577-80.
20. Teede H., Deeks A., Moran L. (2010) Polycystic ovary syndrome: a complex condition with psychological, reproductive and metabolic manifestations that impacts on health BMC Med. 30, 8: 41.
21. Burke B.M., Cunliffe W.J. (1984) The assessment of acne vulgaris - the Leeds technique. Br. J. Dermatol. 111: 83-92.
22. Burkhart C.N., Gottwald L. (2003) Assessment of etiologic agents in acne pathogenesis. Skinmed. 2(4): 222-8.
23. Vexiau P., Chaspoux C., Boudou P. et al. (2000) Role of androgens in female-pattern androgenetic alopecia, either alone or associated with other symptoms of hyperandrogenism. Arch. Dermatol. Res. 292: 598-604.
24. Ehrmann D.A., Rosenfield R.L., Barnes R.B. et al. (1992) Detection of functional ovarian hyperandrogenism in women with androgen excess. N. Engl. J. Med. 327: 157-62.
25. Glueck C.J., Papanna R., Wang P. et al. (2003) Incidence and treatment of metabolic syndrome in newly referred women with confirmed polycystic ovarian syndrome. Metab. Clin. Exp. 52: 908-15.
26. Barth J.H., Yasmin E., Balen A.H. (2007) The diagnosis of polycystic ovary syndrome: the criteria are insufficiently robust for clinical research. Clin. Endocrinol. (Oxf), 67 (6): 811-5.
27. Steck T., Wernze H. (1993) Is determination of the "free androgen index" for hormone screening in polycystic ovaries of value? Gynakol. Geburtshilfliche Rundsch 33(3): 173-9.
28. Escobar-Morreale H.F., Asuncion M., Calvo R.M. et al. (2001) Receiver operating characteristic analysis of the performance of basal serum hormone profiles for the diagnosis of polycystic ovary syndrome in epidemiological studies. Eur. J. Endocrinol. 145(5): 619-24.
29. Miller K.K., Rosner W., Lee H et al. (2004) Measurement of free testosterone in normal women and women with androgen deficiency: comparison of methods. J. Clin. Endocrinol. Metab. 89: 525-33.
30. Van Uytfanghe K., Stockl D., Kaufman J.M. et al. (2004) Evaluation of a candidate reference measurement procedure for serum free testosterone based on ultrafiltration and isotope dilution-gas chromatography-mass spectrometry. Clin. Chem. 50: 2101-10.
31. Knochenhauer E.S., Key T.J., Kahsar-Miller M. et al. (1998) Prevalence of the polycystic ovary syndrome in unselected black and white women of the southeastern United States: a prospective study. J. Clin. Endocrinol. Metab. 83: 3078-82.
32. Komindr S., Kurtz B.R., Stevens M.D. et al. (1986) Relative sensitivity and responsivity of serum cortisol and two adrenal androgens to alpha-adrenocorticotropin-(1-24) in normal and obese, nonhirsute, eumenorrheic women. J. Clin. Endocrinol. Metab. 63(4): 860-4.
33. Yildiz B.O., Woods K.S., Stanczyk F. et al. (2004) Stability of adrenocortical steroidogenesis over time in healthy women and women with polycystic ovary syndrome. J. Clin. Endocrinol. Metab. 89(11): 5558-62.
34. Kumar A., Woods K.S., Bartolucci A.A. et al. (2005) Prevalence of adrenal androgen excess in patients with the polycystic ovary syndrome (PCOS). Clin. Endocrinol. (Oxf); 62: 644-9.
35. Consensus on infertility treatment related to polycystic ovary syndrome. The Thessaloniki ESHRE/ASRM-Sponsored PCOS Consensus Workshop Group March 2-3, (2007), Thessaloniki, Greece. Fertility and Sterility 2008: 505-522.
36. Legro R.S.; Azziz R., Giudice L. (2006) A twenty-first century research agenda for polycystic ovary syndrome. Best Practice & Research Clinical Endocrinology & Metabolism 20: 331-336.
37. Nestler J.E. (2008) Metformin in the treatment of infertility in polycystic ovarian syndrome: an alternative perspective YPERLINK"http://vls2.icm.edu.pl/cgi-bin/sci serv.pl?collection=elsevier&journal=00150282" Fertility and Sterility 90: 14-16.
38. Dunaif A. (2010) Hyperandrogenemia is neceesary but not sufficient for polycystic ovary syndrome. Fertil. Steril. 80: 262-263.